|
1
|
Kohlmann W and Gruber SB: Lynch Syndrome.
Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K
and Amemiya A: GeneReviews® [Internet]. Seattle (WA).
University of Washington; Seattle: 1993-2018
|
|
2
|
Dodaro C, Grifasi C, Florio J, Santangelo
ML, Duraturo F, De Rosa M, Izzo P and Renda A: The role of mutation
analysis of the APC gene in the management of FAP patients. A
controversial issue. Ann Ital Chir. 87:321–325. 2016.PubMed/NCBI
|
|
3
|
Lynch HT, Snyder CL, Shaw TG, Heinen CD
and Hitchins MP: Milestones of Lynch syndrome: 1895–2015. Nat Rev
Cancer. 15:181–194. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
De Rosa M, Galatola M, Borriello S,
Duraturo F, Masone S and Izzo P: Implication of adenomatous
polyposis coli and MUTYH mutations in familial colorectal
polyposis. Dis Colon Rectum. 52:268–274. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Galatola M, Paparo L, Duraturo F, Turano
M, Rossi GB, Izzo P and De Rosa M: Beta catenin and cytokine
pathway dysregulation in patients with manifestations of the ‘PTEN
hamartoma tumor syndrome’. BMC Med Genet. 13:282012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Paparo L, Rossi GB, Delrio P, Rega D,
Duraturo F, Liccardo R, Debellis M, Izzo P and De Rosa M:
Differential expression of PTEN gene correlates with phenotypic
heterogeneity in three cases of patients showing clinical
manifestations of PTEN hamartoma tumour syndrome. Hered Cancer Clin
Pract. 11:82013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carlomagno N, Duraturo F, Candida M, De
Rosa M, Varone V, Ciancia G, Calogero A and Santangelo ML: Multiple
splenic hamartomas and familial adenomatous polyposis: A case
report and review of the literature. J Med Case Rep. 9:1542015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cudia B, Liccardo R, Di Carlo G, Damiano
G, Lo Monte AI, Izzo P and Duraturo F: Clinical and anamnestic
evaluation rôle for the diagnosis and treatment of families
affected by Lynch syndrome. Case report and review of the
literature. Eur J Oncol. 19:265–271. 2014.
|
|
9
|
Liccardo R, De Rosa M, Izzo P and Duraturo
F: Novel implications in molecular diagnosis of Lynch syndrome.
Gastroenterol Res Pract. 2017:25950982017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peltomäki P: Deficient DNA mismatch
repair: A common etiologic factor for colon cancer. Hum Mol Genet.
10:735–740. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gupta R, Sinha S and Paul RN: The impact
of microsatellite stability status in colorectal cancer. Curr Probl
Cancer. 42:548–559. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yurgelun MB, Kulke MH, Fuchs CS, Allen BA,
Uno H, Hornick JL, Ukaegbu CI, Brais LK, McNamara PG, Mayer RJ, et
al: Cancer susceptibility gene mutations in individuals with
colorectal cancer. J Clin Oncol. 35:1086–1095. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lucci-Cordisco E, Rovella V, Carrara S,
Percesepe A, Pedroni M, Bellacosa A, Caluseriu O, Forasarig M, Anti
M, Neri G, et al: Mutations of the ‘minor’ mismatch repair gene
MSH6 in typical and atypical hereditary nonpolyposis colorectal
cancer. Fam Cancer. 1:93–99. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Agostini M, Tibiletti MG, Lucci-Cordisco
E, Chiaravalli A, Morreau H, Furlan D, Boccuto L, Pucciarelli S,
Capella C, Boiocchi M and Viel A: Two PMS2 mutations in a Turcot
syndrome family with small bowel cancers. Am J Gastroenterol.
100:1886–1891. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Duraturo F, Liccardo R and Izzo P:
Coexistence of MLH3 germline variants in colon cancer patients
belonging to families with Lynch syndrome-associated brain tumors.
J Neurooncol. 129:577–578. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Duraturo F, Liccardo R, Cavallo A, De Rosa
M, Grosso M and Izzo P: Association of low-risk MSH3 and MSH2
variant alleles with Lynch syndrome: Probability of synergistic
effects. Int J Cancer. 129:1643–1650. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Adam R, Spier I, Zhao B, Kloth M, Marquez
J, Hinrichsen I, Kirfel J, Tafazzoli A, Horpaopan S, Uhlhaas S, et
al: Exome sequencing identifies biallelic MSH3 germline mutations
as a recessive subtype of colorectal adenomatous polyposis. Am J
Hum Genet. 99:337–351. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Boland CR: Recent discoveries in the
molecular genetics of Lynch syndrome. Fam Cancer. 15:395–403. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Y, Cheong N, Miura M and Iliakis G:
Overexpression of insulin-like growth factor (IGF)-I receptor
enhances inhibition of DNA replication in mouse cells exposed to
x-rays. Radiat Environ Biophys. 36:117–123. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Plaschke J, Krüger S, Jeske B, Theissig F,
Kreuz FR, Pistorius S, Saeger HD, Iaccarino I, Marra G and
Schackert HK: Loss of MSH3 protein expression is frequent in
MLH1-deficient colorectal cancer and is associated with disease
progression. Cancer Res. 64:864–870. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Loukola A, Vilkki S, Singh J, Launonen V
and Aaltonen LA: Germline and somatic mutation analysis of MLH3 in
MSI-positive colorectal cancer. Am J Pathol. 157:347–352. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Alhopuro P, Sammalkorpi H, Niittymäki I,
Biström M, Raitila A, Saharinen J, Nousiainen K, Lehtonen HJ,
Heliövaara E, Puhakka J, et al: Candidate driver genes in
microsatellite-unstable colorectal cancer. Int J Cancer.
130:1558–1566. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ryan E, Sheahan K, Creavin B, Mohan HM and
Winter DC: The current value of determining the mismatch repair
status of colorectal cancer: A rationale for routine testing. Crit
Rev Oncol Hematol. 116:38–57. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang L, Cunningham JM, Winters JL,
Guenther JC, French AJ, Boardman LA, Burgart LJ, McDonnell SK,
Schaid DJ and Thibodeau SN: BRAF mutations in colon cancer are not
likely attributable to defective DNA mismatch repair. Cancer Res.
63:5209–5212. 2003.PubMed/NCBI
|
|
25
|
Carethers JM, Koi M and Tseng-Rogenski SS:
EMAST is a form of microsatellite instability that is initiated by
inflammation and modulates colorectal cancer progression. Genes
(Basel). 6:185–205. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vasen HF, Mecklin JP, Watson P, Utsunomiya
J, Bertario L, Lynch P, Svendsen LB, Cristofaro G, Müller H, Khan
PM, et al: Surveillance in hereditary nonpolyposis colorectal
cancer: An international cooperative study of 165 families. The
International Collaborative Group on HNPCC. Dis Colon Rectum.
36:1–4. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vasen HF, Watson P, Mecklin JP and Lynch
HT: New clinical criteria for hereditary nonpolyposis colorectal
cancer (HNPCC, Lynch syndrome) proposed by the International
Collaborative group on HNPCC. Gastroenterology. 116:1453–1456.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Boland CR, Thibodeau SN, Hamilton SR,
Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA,
Fodde R, Ranzani GN and Srivastava S: A National Cancer Institute
Workshop on Microsatellite Instability for cancer detection and
familial predisposition: Development of international criteria for
the determination of microsatellite instability in colorectal
cancer. Cancer Res. 58:5248–5257. 1998.PubMed/NCBI
|
|
29
|
Umar A, Boland CR, Terdiman JP, Syngal S,
de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ,
Hamelin R, et al: Revised bethesda guidelines for hereditary
nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite
instability. J Natl Cancer Inst. 96:261–268. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vilar E, Mork ME, Cuddy A, Borras E,
Bannon SA, Taggart MW, Ying J, Broaddus RR, Luthra R,
Rodriguez-Bigas MA, et al: Role of microsatellite instability-low
as a diagnostic biomarker of Lynch syndrome in colorectal cancer.
Cancer Genet. 207:495–502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Suraweera N, Duval A, Reperant M, Vaury C,
Furlan D, Leroy K, Seruca R, Iacopetta B and Hamelin R: Evaluation
of tumor microsatellite instability using five quasimonomorphic
mononucleotide repeats and pentaplex PCR. Gastroenterology.
123:1804–1811. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Buhard O, Suraweera N, Lectard A, Duval A
and Hamelin R: Quasimonomorphic mononucleotide repeats for
high-level microsatellite instability analysis. Dis Markers.
20:251–257. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lynch PM: The hMSH2 and hMLH1 genes in
hereditary nonpolyposis colorectal cancer. Surg Oncol Clin N Am.
18:611–624. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liccardo R, De Rosa M, Rossi GB,
Carlomagno N, Izzo P and Duraturo F: Incomplete segregation of MSH6
frameshift variants with phenotype of lynch syndrome. Int J Mol
Sci. 18(pii): E9992017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Duraturo F, Cavallo A, Liccardo R, Cudia
B, De Rosa M, Diana G and Izzo P: Contribution of large genomic
rearrangements in Italian Lynch syndrome patients: Characterization
of a novel alu-mediated deletion. Biomed Res Int. 2013:2198972013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liccardo R, De Rosa M, Rossi GB, Rigler G,
Izzo P and Duraturo F: Characterization of novel, large
duplications in the MSH2 gene of three unrelated Lynch syndrome
patients. Cancer Genet. 221:19–24. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rasmussen LJ, Heinen CD, Royer-Pokora B,
Drost M, Tavtigian S, Hofstra RM and de Wind N: Pathological
assessment of mismatch repair gene variants in Lynch syndrome:
Past, present, and future. Hum Mutat. 33:1617–1625. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Duraturo F, Liccardo R, Cavallo A, De Rosa
M, Rossi GB and Izzo P: Multivariate analysis as a method for
evaluating the pathogenicity of novel genetic MLH1 variants in
patients with colorectal cancer and microsatellite instability. Int
J Mol Med. 36:511–517. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Goldgar DE, Easton DF, Byrnes GB, Spurdle
AB, Iversen ES and Greenblatt MS; IARC Unclassified Genetic
Variants Working Group, : Genetic evidence and integration of
various data sources for classifying uncertain variants into a
single model. Hum Mutat. 29:1265–1272. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kheirelseid EA, Miller N, Chang KH, Curran
C, Hennessey E, Sheehan M and Kerin MJ: Mismatch repair protein
expression in colorectal cancer. J Gastrointest Oncol. 4:397–408.
2013.PubMed/NCBI
|
|
41
|
Jansen AM, van Wezel T, van den Akker BE,
Ventayol Garcia M, Ruano D, Tops CM, Wagner A, Letteboer TG,
Gómez-García EB, Devilee P, et al: Combined mismatch repair and
POLE/POLD1 defects explain unresolved suspected Lynch syndrome
cancers. Eur J Hum Genet. 24:1089–1092. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zanotti KJ and Gearhart PJ: Antibody
diversification caused by disrupted mismatch repair and promiscuous
DNA polymerases. DNA Repair (Amst). 38:110–116. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Davari K, Frankenberger S, Schmidt A, Tomi
NS and Jungnickel B: Checkpoint kinase 2 is required for efficient
immunoglobulin diversification. Cell Cycle. 13:3659–3669. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bak ST, Sakellariou D and Pena-Diaz J: The
dual nature of mismatch repair as antimutator and mutator: For
better or for worse. Front Genet. 5:2872014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Schwitalle Y, Linnebacher M, Ripberger E,
Gebert J and von Knebel Doeberitz M: Immunogenic peptides generated
by frameshift mutations in DNA mismatch repair-deficient cancer
cells. Cancer Immun. 4:142004.PubMed/NCBI
|
|
46
|
Schwitalle Y, Kloor M, Eiermann S,
Linnebacher M, Kienle P, Knaebel HP, Tariverdian M, Benner A and
von Knebel Doeberitz M: Immune response against frameshift-induced
neopeptides in HNPCC patients and healthy HNPCC mutation carriers.
Gastroenterology. 134:988–997. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Koi M, Tseng-Rogenski SS and Carethers JM:
Inflammation-associated microsatellite alterations: Mechanisms and
significance in the prognosis of patients with colorectal cancer.
World J Gastrointest Oncol. 10:1–14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bilgin B, Sendur MA, Bülent Akıncı M,
Şener Dede D and Yalçın B: Targeting the PD-1 pathway: A new hope
for gastrointestinal cancers. Curr Med Res Opin. 33:749–759. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Link JT and Overman MJ: Immunotherapy
progress in mismatch repair-deficient colorectal cancer and future
therapeutic challenges. Cancer J. 22:190–195. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Dominguez-Valentin M, Nakken S, Tubeuf H,
Vodak D, Ekstrøm PO, Nissen AM, Morak M, Holinski-Feder E, Martins
A, Møller P and Hovig E: Identification of genetic variants for
clinical management of familial colorectal tumors. BMC Med Genet.
19:262018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Giardiello FM, Allen JI, Axilbund JE,
Boland CR, Burke CA, Burt RW, Church JM, Dominitz JA, Johnson DA,
Kaltenbach T, et al: Guidelines on genetic evaluation and
management of Lynch syndrome: A consensus statement by the US
Multi-society task force on colorectal cancer. Am J Gastroenterol.
109:1159–1179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kanga-Parabia A, Gaff C, Flander L,
Jenkins M and Keogh LA: Discussions about predictive genetic
testing for Lynch syndrome: The role of health professionals and
families in decisions to decline. Fam Cancer. 17:547–555. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lindberg LJ, Ladelund S, Frederiksen BL,
Smith-Hansen L and Bernstein I: Outcome of 24 years national
surveillance in different hereditary colorectal cancer subgroups
leading to more individualised surveillance. J Med Genet.
54:297–304. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Aissaoui S, Cartellier C, Seytier T,
Giraud S and Calender A: Genetic mutation risk calculation in Lynch
syndrome inheritance: Evaluating the utility of the
PREMM1,2,6 model in Lyon: The first French study. Bull
Cancer. 104:288–294. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Dillon JL, Gonzalez JL, DeMars L, Bloch KJ
and Tafe LJ: Universal screening for Lynch syndrome in endometrial
cancers: Frequency of germline mutations and identification of
patients with Lynch-like syndrome. Hum Pathol. 70:121–128. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
De Rosa M, Rega D, Costabile V, Duraturo
F, Niglio A, Izzo P, Pace U and Delrio P: The biological complexity
of colorectal cancer: Insights into biomarkers for early detection
and personalized care. Therap Adv Gastroenterol. 9:861–886. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wojas-Krawczyk K, Kalinka-Warzocha E,
Reszka K, Nicoś M, Szumiło J, Mańdziuk S, Szczepaniak K, Kupnicka
D, Lewandowski R, Milanowski J and Krawczyk P: Analysis of KRAS,
NRAS, BRAF, and PIK3CA mutations could predict metastases in
colorectal cancer: A preliminary study. Adv Clin Exp Med.
7:Aug;2018.[Epub ahead of print].
|
|
58
|
Murcia O, Juárez M, Rodríguez-Soler M,
Hernández-Illán E, Giner-Calabuig M, Alustiza M, Egoavil C,
Castillejo A, Alenda C, Barberá V, et al: Colorectal cancer
molecular classification using BRAF, KRAS, microsatellite
instability and CIMP status: Prognostic implications and response
to chemotherapy. PLoS One. 13:e02030512018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Romera A, Peredpaya S, Shparyk Y,
Bondarenko I, Mendonça Bariani G, Abdalla KC, Roca E, Franke F,
Melo Cruz F, Ramesh A, et al: Bevacizumab biosimilar BEVZ92 versus
reference bevacizumab in combination with FOLFOX or FOLFIRI as
first-line treatment for metastatic colorectal cancer: A
multicentre, open-label, randomised controlled trial. Lancet
Gastroenterol Hepatol. 3:845–855. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Li LS, Morales JC, Veigl M, Sedwick D,
Greer S, Meyers M, Wagner M, Fishel R and Boothman DA: DNA mismatch
repair (MMR)-dependent 5-fluorouracil cytotoxicity and the
potential for new therapeutic targets. Br J Pharmacol. 158:679–692.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
O'Neil BH, Wallmark JM, Lorente D, Elez E,
Raimbourg J, Gomez-Roca C, Ejadi S, Piha-Paul SA, Stein MN, Abdul
Razak AR, et al: Safety and antitumor activity of the anti-PD-1
antibody pembrolizumab in patients with advanced colorectal
carcinoma. PLoS One. 12:e01898482017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
von Knebel Doeberitz M and Kloor M:
Towards a vaccine to prevent cancer in Lynch syndrome patients. Fam
Cancer. 12:307–312. 2013. View Article : Google Scholar : PubMed/NCBI
|
